FDA Approved Sarclisa For The Treatment Of  Multiple Myeloma 

Sarclisa (isatuximab-irfc) is a promising new treatment for multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is an antibody that targets the CD38 protein, which is highly expressed on the surface of multiple myeloma cells. Sarclisa is designed to work in patients with previously treated multiple myeloma, where other treatments have not worked or have stopped working. 

How Sarclisa Works

Sarclisa is an antibody that targets the CD38 protein, which is highly expressed on the surface of multiple myeloma cells. By binding to CD38, Sarclisa triggers the immune system to attack and kill the cancer cells. Sarclisa is typically given in combination with other drugs, such as pomalidomide and dexamethasone, to enhance its effectiveness in treating multiple myeloma.

Sarclisa (isatuximab-irfc) is an intravenous injection for the treatment of certain cancers, available in two formulations: 100 mg/5 mL and 500 mg/25 mL, both in single-dose vials.

Clinical Advancements And Efficacy

Clinical trials have demonstrated the significant efficacy of Sarclisa in patients with previously treated multiple myeloma. In a phase 3 clinical trial, Sarclisa in combination with pomalidomide and dexamethasone demonstrated improved progression-free survival compared to pomalidomide and dexamethasone alone in this patient population. The drug has also shown promising results in other clinical trials, further underscoring its potential in addressing multiple myeloma.

Safety and Future Implications

While Sarclisa has exhibited potent anti-tumor activity, it is important to note that, like many targeted therapies, it can also affect healthy cells, leading to potential side effects. However, the development of Sarclisa represents a significant advancement in precision oncology, offering a more tailored and effective approach to treating multiple myeloma with fewer off-target side effects compared to previous treatments.

For those looking to buy Sarclisa online, exclusively available in the US and Europe, Sansfro Health presents a trustworthy option. Dedicated to simplifying the importation process, Sansfro Health furnishes accurate pricing information for a seamless experience. Sansfro facilitates the importation with genuine pricing and comprehensive support.

Individuals considering medication importation are required to furnish a valid prescription, identity proof, details of the healthcare professional, and current address. The Sansfro team initiates the application for an import license, ensuring access to the required medication upon government approval. To inquire about the cost of Sarclisa in India and comprehend the importation procedure, individuals can contact the Patient Support Team at (+91) 93157 05373 or via email at help@sansfro.com.

Reference:

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761113s000lbl.pdf  
2.  https://www.myeloma.org/blog/dr-duries/2023-mid-year-myeloma-update 
3. https://reference.medscape.com/drug/sarclisa-isatuximab-4000022 
4. https://www.drugs.com/sarclisa.html